SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Hamrin V, Scahill L. Issues Ment. Health Nurs. 2005; 26(4): 433-450.

Affiliation

Yale University School of Nursing and West Haven Mental Health Center, New Haven, CT, USA.

Copyright

(Copyright © 2005, Informa - Taylor and Francis Group)

DOI

10.1080/01612840590922452

PMID

16020058

Abstract

Recent warnings about potential serious adverse effects with the selective serotonin reuptake inhibitors in children and adolescents with depression raises questions about the risk-benefit ratio of these drugs in this population. Published safety and efficacy trials of SSRIs for the treatment of youth with depression are critically reviewed. These data were augmented by information from regulatory hearings in 2003-2004 and selected open-label reports. Based on this review, recommendations for medication treatment and monitoring of children and adolescents with major depression on SSRIs are provided. Emerging data from several clinical trials show that the SSRIs provide moderate benefits for youth with depression. In addition, SSRI treatment may be associated with increased risk of behavioral activation, self-harm, and suicidal ideation. Appropriate use of the SSRIs in children and adolescents requires careful diagnostic assessment, evaluation of comorbidity, and close monitoring, especially early in treatment.

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print